Prognostic value of p53 expression in hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer patients receiving neoadjuvant chemotherapy
Purpose The aim of this study was to determine whether the outcome to neoadjuvant chemotherapy (NAC) can be predicted by analyzing p53 expression in hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients. Methods We retrospectively reviewed...
Gespeichert in:
| Veröffentlicht in: | Breast cancer research and treatment 2021-06, Vol.187 (2), p.447-454 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 454 |
|---|---|
| container_issue | 2 |
| container_start_page | 447 |
| container_title | Breast cancer research and treatment |
| container_volume | 187 |
| creator | Albinsaad, Loai Saleh Kim, Jisun Chung, Il Yong Ko, Beom Seok Kim, Hee Jeong Lee, Jong Won Son, Byung Ho Ahn, Sei-Hyun Lee, Sae Byul |
| description | Purpose
The aim of this study was to determine whether the outcome to neoadjuvant chemotherapy (NAC) can be predicted by analyzing p53 expression in hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients.
Methods
We retrospectively reviewed 594 patients diagnosed with stage I–III HR-positive, HER2-negative breast cancer, and treated with NAC at the Asan Medical Center between 2008 and 2014. Expression of p53 was assessed, and overall survival (OS) and breast cancer-specific survival (BCSS) were investigated and compared between groups.
Results
At a median follow-up period of 69.8 months, OS and BCSS were higher in the p53-negative (p53(−)) group than in the p53-positive (p53(+)) group. Five-year OS was 95.4% in the p53(−) and 92.1% in the p53(+) group (
p
= 0.005). BCSS was 96.2% in the p53(−) group and 93% in the p53(+) group (
p
= 0.008).
Conclusion
High expression of immunohistochemically detected p53 was strongly and significantly associated with decreased OS and BCSS than low p53 expression, suggesting that p53 may be a powerful prognostic factor in HR-positive, HER2-negative breast cancer patients receiving NAC. |
| doi_str_mv | 10.1007/s10549-021-06134-6 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2491061667</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A666291545</galeid><sourcerecordid>A666291545</sourcerecordid><originalsourceid>FETCH-LOGICAL-c473t-cad44c27a40273851fa391725bf97e77b396f88754ca92cbf1871294f0ecb0c33</originalsourceid><addsrcrecordid>eNp9ks1u1DAUhSMEokPhBVggS0iITYp_EjteVhV_UiVYwNpynJvEo8QOtjPQp-or1jNTWooQ8sLS9XeO7vU9RfGS4DOCsXgXCa4rWWJKSswJq0r-qNiQWrBSUCIeFxtMuCh5g_lJ8SzGLcZYCiyfFieM1VI2XGyK66_BD87HZA3a6WkF5Hu01AzBryVAjNY7ZB0afZi9AxTAwJJ8KBcfbbI7QNp1aFxn7RAstoMw6wkNwf9MI-q1yeidBtHSwaAPqjaAjgkZ7QwEtOQiuBQPqN1ZNyAHXnfbdaddpkaYfRoh6OXqefGk11OEF7f3afH9w_tvF5_Kyy8fP1-cX5amEiyVRndVZajQFaaCNTXpNZNE0LrtpQAhWiZ53zSiroyW1LQ9aQShsuoxmBYbxk6Lt0ffJfgfK8SkZhsNTJPOna1R0UqS_Omci4y-_gvd-jW43J2iNZNMCorre2rQEyjrep-CNntTdc45p5LU1Z46-weVTwezNXkDvc31B4I3fwhG0FMao5_WlBcXH4L0CJrgYwzQqyXYWYcrRbDax0kd46RynNQhTopn0avb0dZ2hu5O8js_GWBHIOYnN0C4n_0_tjfQM9b3</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2539397205</pqid></control><display><type>article</type><title>Prognostic value of p53 expression in hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer patients receiving neoadjuvant chemotherapy</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Albinsaad, Loai Saleh ; Kim, Jisun ; Chung, Il Yong ; Ko, Beom Seok ; Kim, Hee Jeong ; Lee, Jong Won ; Son, Byung Ho ; Ahn, Sei-Hyun ; Lee, Sae Byul</creator><creatorcontrib>Albinsaad, Loai Saleh ; Kim, Jisun ; Chung, Il Yong ; Ko, Beom Seok ; Kim, Hee Jeong ; Lee, Jong Won ; Son, Byung Ho ; Ahn, Sei-Hyun ; Lee, Sae Byul</creatorcontrib><description>Purpose
The aim of this study was to determine whether the outcome to neoadjuvant chemotherapy (NAC) can be predicted by analyzing p53 expression in hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients.
Methods
We retrospectively reviewed 594 patients diagnosed with stage I–III HR-positive, HER2-negative breast cancer, and treated with NAC at the Asan Medical Center between 2008 and 2014. Expression of p53 was assessed, and overall survival (OS) and breast cancer-specific survival (BCSS) were investigated and compared between groups.
Results
At a median follow-up period of 69.8 months, OS and BCSS were higher in the p53-negative (p53(−)) group than in the p53-positive (p53(+)) group. Five-year OS was 95.4% in the p53(−) and 92.1% in the p53(+) group (
p
= 0.005). BCSS was 96.2% in the p53(−) group and 93% in the p53(+) group (
p
= 0.008).
Conclusion
High expression of immunohistochemically detected p53 was strongly and significantly associated with decreased OS and BCSS than low p53 expression, suggesting that p53 may be a powerful prognostic factor in HR-positive, HER2-negative breast cancer patients receiving NAC.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1007/s10549-021-06134-6</identifier><identifier>PMID: 33599867</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Adjuvant treatment ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Breast cancer ; Breast Neoplasms - drug therapy ; Cancer ; Cancer patients ; Cancer research ; Chemotherapy ; Chemotherapy, Adjuvant ; Clinical Trial ; Comparative analysis ; Epidermal growth factor ; ErbB-2 protein ; Female ; Health aspects ; Hormones - therapeutic use ; Humans ; Medical centers ; Medical colleges ; Medicine ; Medicine & Public Health ; Neoadjuvant Therapy ; Oncology ; p53 Protein ; Prognosis ; Receptor, ErbB-2 - genetics ; Receptor, ErbB-2 - metabolism ; Receptors, Progesterone ; Retrospective Studies ; Survival ; Triple Negative Breast Neoplasms - drug therapy ; Tumor proteins ; Tumor Suppressor Protein p53 - genetics</subject><ispartof>Breast cancer research and treatment, 2021-06, Vol.187 (2), p.447-454</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature 2021</rights><rights>COPYRIGHT 2021 Springer</rights><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c473t-cad44c27a40273851fa391725bf97e77b396f88754ca92cbf1871294f0ecb0c33</citedby><cites>FETCH-LOGICAL-c473t-cad44c27a40273851fa391725bf97e77b396f88754ca92cbf1871294f0ecb0c33</cites><orcidid>0000-0002-3370-6937</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10549-021-06134-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10549-021-06134-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33599867$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Albinsaad, Loai Saleh</creatorcontrib><creatorcontrib>Kim, Jisun</creatorcontrib><creatorcontrib>Chung, Il Yong</creatorcontrib><creatorcontrib>Ko, Beom Seok</creatorcontrib><creatorcontrib>Kim, Hee Jeong</creatorcontrib><creatorcontrib>Lee, Jong Won</creatorcontrib><creatorcontrib>Son, Byung Ho</creatorcontrib><creatorcontrib>Ahn, Sei-Hyun</creatorcontrib><creatorcontrib>Lee, Sae Byul</creatorcontrib><title>Prognostic value of p53 expression in hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer patients receiving neoadjuvant chemotherapy</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><addtitle>Breast Cancer Res Treat</addtitle><description>Purpose
The aim of this study was to determine whether the outcome to neoadjuvant chemotherapy (NAC) can be predicted by analyzing p53 expression in hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients.
Methods
We retrospectively reviewed 594 patients diagnosed with stage I–III HR-positive, HER2-negative breast cancer, and treated with NAC at the Asan Medical Center between 2008 and 2014. Expression of p53 was assessed, and overall survival (OS) and breast cancer-specific survival (BCSS) were investigated and compared between groups.
Results
At a median follow-up period of 69.8 months, OS and BCSS were higher in the p53-negative (p53(−)) group than in the p53-positive (p53(+)) group. Five-year OS was 95.4% in the p53(−) and 92.1% in the p53(+) group (
p
= 0.005). BCSS was 96.2% in the p53(−) group and 93% in the p53(+) group (
p
= 0.008).
Conclusion
High expression of immunohistochemically detected p53 was strongly and significantly associated with decreased OS and BCSS than low p53 expression, suggesting that p53 may be a powerful prognostic factor in HR-positive, HER2-negative breast cancer patients receiving NAC.</description><subject>Adjuvant treatment</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Cancer</subject><subject>Cancer patients</subject><subject>Cancer research</subject><subject>Chemotherapy</subject><subject>Chemotherapy, Adjuvant</subject><subject>Clinical Trial</subject><subject>Comparative analysis</subject><subject>Epidermal growth factor</subject><subject>ErbB-2 protein</subject><subject>Female</subject><subject>Health aspects</subject><subject>Hormones - therapeutic use</subject><subject>Humans</subject><subject>Medical centers</subject><subject>Medical colleges</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neoadjuvant Therapy</subject><subject>Oncology</subject><subject>p53 Protein</subject><subject>Prognosis</subject><subject>Receptor, ErbB-2 - genetics</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Receptors, Progesterone</subject><subject>Retrospective Studies</subject><subject>Survival</subject><subject>Triple Negative Breast Neoplasms - drug therapy</subject><subject>Tumor proteins</subject><subject>Tumor Suppressor Protein p53 - genetics</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9ks1u1DAUhSMEokPhBVggS0iITYp_EjteVhV_UiVYwNpynJvEo8QOtjPQp-or1jNTWooQ8sLS9XeO7vU9RfGS4DOCsXgXCa4rWWJKSswJq0r-qNiQWrBSUCIeFxtMuCh5g_lJ8SzGLcZYCiyfFieM1VI2XGyK66_BD87HZA3a6WkF5Hu01AzBryVAjNY7ZB0afZi9AxTAwJJ8KBcfbbI7QNp1aFxn7RAstoMw6wkNwf9MI-q1yeidBtHSwaAPqjaAjgkZ7QwEtOQiuBQPqN1ZNyAHXnfbdaddpkaYfRoh6OXqefGk11OEF7f3afH9w_tvF5_Kyy8fP1-cX5amEiyVRndVZajQFaaCNTXpNZNE0LrtpQAhWiZ53zSiroyW1LQ9aQShsuoxmBYbxk6Lt0ffJfgfK8SkZhsNTJPOna1R0UqS_Omci4y-_gvd-jW43J2iNZNMCorre2rQEyjrep-CNntTdc45p5LU1Z46-weVTwezNXkDvc31B4I3fwhG0FMao5_WlBcXH4L0CJrgYwzQqyXYWYcrRbDax0kd46RynNQhTopn0avb0dZ2hu5O8js_GWBHIOYnN0C4n_0_tjfQM9b3</recordid><startdate>20210601</startdate><enddate>20210601</enddate><creator>Albinsaad, Loai Saleh</creator><creator>Kim, Jisun</creator><creator>Chung, Il Yong</creator><creator>Ko, Beom Seok</creator><creator>Kim, Hee Jeong</creator><creator>Lee, Jong Won</creator><creator>Son, Byung Ho</creator><creator>Ahn, Sei-Hyun</creator><creator>Lee, Sae Byul</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3370-6937</orcidid></search><sort><creationdate>20210601</creationdate><title>Prognostic value of p53 expression in hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer patients receiving neoadjuvant chemotherapy</title><author>Albinsaad, Loai Saleh ; Kim, Jisun ; Chung, Il Yong ; Ko, Beom Seok ; Kim, Hee Jeong ; Lee, Jong Won ; Son, Byung Ho ; Ahn, Sei-Hyun ; Lee, Sae Byul</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c473t-cad44c27a40273851fa391725bf97e77b396f88754ca92cbf1871294f0ecb0c33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adjuvant treatment</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Cancer</topic><topic>Cancer patients</topic><topic>Cancer research</topic><topic>Chemotherapy</topic><topic>Chemotherapy, Adjuvant</topic><topic>Clinical Trial</topic><topic>Comparative analysis</topic><topic>Epidermal growth factor</topic><topic>ErbB-2 protein</topic><topic>Female</topic><topic>Health aspects</topic><topic>Hormones - therapeutic use</topic><topic>Humans</topic><topic>Medical centers</topic><topic>Medical colleges</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neoadjuvant Therapy</topic><topic>Oncology</topic><topic>p53 Protein</topic><topic>Prognosis</topic><topic>Receptor, ErbB-2 - genetics</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Receptors, Progesterone</topic><topic>Retrospective Studies</topic><topic>Survival</topic><topic>Triple Negative Breast Neoplasms - drug therapy</topic><topic>Tumor proteins</topic><topic>Tumor Suppressor Protein p53 - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Albinsaad, Loai Saleh</creatorcontrib><creatorcontrib>Kim, Jisun</creatorcontrib><creatorcontrib>Chung, Il Yong</creatorcontrib><creatorcontrib>Ko, Beom Seok</creatorcontrib><creatorcontrib>Kim, Hee Jeong</creatorcontrib><creatorcontrib>Lee, Jong Won</creatorcontrib><creatorcontrib>Son, Byung Ho</creatorcontrib><creatorcontrib>Ahn, Sei-Hyun</creatorcontrib><creatorcontrib>Lee, Sae Byul</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Albinsaad, Loai Saleh</au><au>Kim, Jisun</au><au>Chung, Il Yong</au><au>Ko, Beom Seok</au><au>Kim, Hee Jeong</au><au>Lee, Jong Won</au><au>Son, Byung Ho</au><au>Ahn, Sei-Hyun</au><au>Lee, Sae Byul</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic value of p53 expression in hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer patients receiving neoadjuvant chemotherapy</atitle><jtitle>Breast cancer research and treatment</jtitle><stitle>Breast Cancer Res Treat</stitle><addtitle>Breast Cancer Res Treat</addtitle><date>2021-06-01</date><risdate>2021</risdate><volume>187</volume><issue>2</issue><spage>447</spage><epage>454</epage><pages>447-454</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><abstract>Purpose
The aim of this study was to determine whether the outcome to neoadjuvant chemotherapy (NAC) can be predicted by analyzing p53 expression in hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients.
Methods
We retrospectively reviewed 594 patients diagnosed with stage I–III HR-positive, HER2-negative breast cancer, and treated with NAC at the Asan Medical Center between 2008 and 2014. Expression of p53 was assessed, and overall survival (OS) and breast cancer-specific survival (BCSS) were investigated and compared between groups.
Results
At a median follow-up period of 69.8 months, OS and BCSS were higher in the p53-negative (p53(−)) group than in the p53-positive (p53(+)) group. Five-year OS was 95.4% in the p53(−) and 92.1% in the p53(+) group (
p
= 0.005). BCSS was 96.2% in the p53(−) group and 93% in the p53(+) group (
p
= 0.008).
Conclusion
High expression of immunohistochemically detected p53 was strongly and significantly associated with decreased OS and BCSS than low p53 expression, suggesting that p53 may be a powerful prognostic factor in HR-positive, HER2-negative breast cancer patients receiving NAC.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>33599867</pmid><doi>10.1007/s10549-021-06134-6</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-3370-6937</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-6806 |
| ispartof | Breast cancer research and treatment, 2021-06, Vol.187 (2), p.447-454 |
| issn | 0167-6806 1573-7217 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2491061667 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adjuvant treatment Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast cancer Breast Neoplasms - drug therapy Cancer Cancer patients Cancer research Chemotherapy Chemotherapy, Adjuvant Clinical Trial Comparative analysis Epidermal growth factor ErbB-2 protein Female Health aspects Hormones - therapeutic use Humans Medical centers Medical colleges Medicine Medicine & Public Health Neoadjuvant Therapy Oncology p53 Protein Prognosis Receptor, ErbB-2 - genetics Receptor, ErbB-2 - metabolism Receptors, Progesterone Retrospective Studies Survival Triple Negative Breast Neoplasms - drug therapy Tumor proteins Tumor Suppressor Protein p53 - genetics |
| title | Prognostic value of p53 expression in hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer patients receiving neoadjuvant chemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T19%3A11%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20value%20of%20p53%20expression%20in%20hormone%20receptor-positive%20and%20human%20epidermal%20growth%20factor%20receptor%202-negative%20breast%20cancer%20patients%20receiving%20neoadjuvant%20chemotherapy&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=Albinsaad,%20Loai%20Saleh&rft.date=2021-06-01&rft.volume=187&rft.issue=2&rft.spage=447&rft.epage=454&rft.pages=447-454&rft.issn=0167-6806&rft.eissn=1573-7217&rft_id=info:doi/10.1007/s10549-021-06134-6&rft_dat=%3Cgale_proqu%3EA666291545%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2539397205&rft_id=info:pmid/33599867&rft_galeid=A666291545&rfr_iscdi=true |